España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

apotex europe b.v. - candesartan cilexetilo - excipientes: manitol (e-421),almidon de maiz,glicerol - antagonistas de angiotensina ii, monofÁrmacos - antagonistas de angiotensina ii, monofármacos - candesartán

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

apotex europe b.v. - candesartan cilexetilo - excipientes: manitol (e-421),almidon de maiz,glicerol - antagonistas de angiotensina ii, monofÁrmacos - antagonistas de angiotensina ii, monofármacos - candesartán

Perú - español - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

cardio perfusion e.i.r.ltda. -

Perú - español - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

mckinsey medica sociedad comercial de responsabilidad limitada - mckinsey medica s.r.l. -

Perú - español - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

covidien peru s.a. -

Perú - español - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

covidien peru s.a. -

Perú - español - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

surgicorp sociedad comercial de responsabilidad limitada - surgicorp s.r.l. -

Unión Europea - español - EMA (European Medicines Agency)

stada arzneimittel ag - bevacizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - agentes antineoplásicos - oyavas in combination with fluoropyrimidine based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. oyavas in combination with paclitaxel is indicated for first line treatment of adult patients with metastatic breast cancer. para obtener más información sobre el estado del receptor 2 del factor de crecimiento epidérmico humano (her2), consulte la sección 5. oyavas in combination with capecitabine is indicated for first line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with oyavas in combination with capecitabine. para más información sobre el estado de her2, consulte la sección 5. oyavas, in addition to platinum based chemotherapy, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non small cell lung cancer other than predominantly squamous cell histology. oyavas, in combination with erlotinib, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non squamous non small cell lung cancer with epidermal growth factor receptor (egfr) activating mutations (see section 5. oyavas in combination with interferon alfa 2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. oyavas, in combination with carboplatin and paclitaxel is indicated for the front line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5. oyavas, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor–targeted agents. oyavas, in combination with topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents (see section 5. oyavas, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5.

Cuba - español - CECMED (Autoridad Reguladora de Medicamentos, Equipos y Dispositivos Médicos)

b. braun melsungen ag. - propofol - emulsión para inyección e infusión iv - 10 mg/ml

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

acino ag - telmisartan; hidroclorotiazida - comprimido recubierto con pelÍcula - 80 mg/12,5 mg - telmisartan 80 mg; hidroclorotiazida 12,5 mg - telmisartán y diuréticos